Predictors of hospitalization and institutionalization in Medicaid patient populations with Alzheimer’s Disease


Objectives: Determine predictors of hospitalization and institutionalization in Medicaid populations with Alzheimer’s Disease (AD). Methods: Data were obtained from the Centers for Medicareand Medicaid Services (CMS). Individuals enrolled in Florida,New Jersey, and New York Medicaid programs on January 1, 2004, remained in that program for 1 year and exposed to an AD medication were included. AD diagnosis was based on the ICD-9-CM code 331.0. Outcomes of interest were hospitalization and institutionalization. Multivariate logistic regression models were used to test for the association between outcomes of interest and demographics, resource utilization factors, and type of AD pharmacotherapy exposure. Results: A total of 65,442 individuals qualified for the study. Age was positively and significantly associated with hospitalization (p < 0.001) and institutionalization (p < 0.001). Exposure tomemantine was significantly associated with less chance of hospitalization (OR = 0.88; 99% CI: 0.77 - 0.99). Non-Hispanic Blacks were significantly (p < 0.001) more likely to be hospitalized than Non-Hispanic Whites (OR = 1.60; 99% CI: 1.41 - 1.81). Compared to Non-Hispanic Whites, Non-Hispanic Blacks (OR = 0.73; 99% CI: 0.60 - 0.88), Hispanics (OR = 0.36; 99% CI: 0.27 - 0.47), and Non-Hispanic Others (OR = 0.42; 99% CI: 0.21 - 0.82) were significantly less likely to be institutionalized. Individuals prescribed donepezil (OR = 1.29, 99% CI, 1.08 - 1.54) and galantamine (OR = 1.46, 99% CI: 1.19 - 1.79) were significantly more likely to have an institutionalization claim (p < 0.001 for both medications). Residents of New York were significantly morelikely to be hospitalized than Florida residents (OR = 1.30; 99% CI: 1.17 - 1.44), where as New Jersey residents were significantly less likely to be hospitalized (OR = 0.75; 99% CI: 0.66 - 0.85). Finally, compared toFloridaresidents, residents of New Jerseywere significantly more likely to be institutionalized (OR = 4.61; 99% CI: 3.98 - 5.33). Conclusion: Demographics, state of residence and pharmacotherapy exposure weresignificant predictors of health care service utilization. Further pharmacoeconomic studies in AD medication therapy are warranted.

Share and Cite:

M. Gilligan, A. , C. Malone, D. , L. Warholak, T. and P. Armstrong, E. (2013) Predictors of hospitalization and institutionalization in Medicaid patient populations with Alzheimer’s Disease. Advances in Alzheimer's Disease, 2, 74-82. doi: 10.4236/aad.2013.23011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Alzheimer’s Association (2012) Alzheimer’s disease facts and figures. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 7, 1-72.
[2] Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A. and Evans, D.A. (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Archives of Neurology, 60, 1119-1122. doi:10.1001/archneur.60.8.1119
[3] The Lewin Group (2010) Lewin Model on Alzheimer’s and dementia and costs. The model estimates total payments for community-based health care services using data from the Medicare Current Beneficiary Survey (MCBS).
[4] Bynum, J. and Dartmouth, M.P.H. (2008) Medicare current beneficiary survey. Institute for Health Policy and Clinical Care, Dartmouth Medical School.
[5] Areosa Sastre, A., McShane, R. and Sherriff, F. (2004) Memantine for dementia. Cochrane Database of Systematic Reviews, 4, CD003154.
[6] Birks, J., Grimley, E. J., Iakovidou, V., Tsolaki, M. and Holt, F.E. (2009) Rivastigmine for Alzheimer’s disease. Cochrane Database of Systematic Reviews, 2, CD001191.
[7] Birks, J.S. and Harvey, R. (2003) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews, 3, CD001190.
[8] Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L. and Farlow, M. (1998) Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials. Dementia trialists’ collaboration. Journal of the American Medical Association, 280, 1777-1782. doi:10.1001/jama.280.20.1777
[9] Loy, C. and Schneider, L. (2004) Galantamine for Alzheimer’s disease. Cochrane Data-base of Systematic Reviews, 4, CD001747.
[10] Pouryamout, L., Dams, J., Wasem, J., Dodel, R. and Neumann, A. (2012) Economic evaluation of treatment options in patients with Alzheimer’s disease: A systematic review of cost-effectiveness analyses. Drugs, 72, 789- 802. doi:10.2165/11631830-000000000-00000
[11] Institute of Medicine (2001) Crossing the quality chasm: A new health system for the 21st century. National Academy Press, Washington DC.
[12] Jencks, S.F., Cuerdon, T., Burwen, D.R., Fleming, B., Houck, P.M., Kussmaul, A.E., et al. (2000) Quality of medical care delivered to medicare beneficiaries: A profile at state and national levels. Journal of the American Medical Association, 284, 1670-1676. doi:10.1001/jama.284.13.1670
[13] McGlynn, E.A., Asch, S.M., Adams, J., Keesey, J., Hicks, J., DeCristofaro, A., et al. (2003) The quality of health care delivered to adults in the United States. The New England Journal of Medicine, 348, 2635-2645. doi:10.1056/NEJMsa022615
[14] Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.C., et al. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care, 43, 1130-1139. doi:10.1097/01.mlr.0000182534.19832.83
[15] Charlson, M.E., Pompei, P., Ales, K.L. and MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40, 373-383. doi:10.1016/0021-9681(87)90171-8
[16] Yang, Z., Zhang, K., Lin, P.J., Clevenger, C. and Atherly, A.A. (2012) Longitudinal analysis of the lifetime cost of dementia. Health Services Research; 47(4): 1660-1678. doi:10.1111/j.1475-6773.2011.01365.x
[17] Schulz, R., Belle, S.H., Czaja, S.J., McGinnis, K.A., Stevens, A. and Zhang, S. (2004) Longterm care placement of dementia patients and caregiver health and well-being. Journal of the American Medical Association, 292, 961-967. doi:10.1001/jama.292.8.961
[18] McClendon, M.J., Smyth, K.A. and Neundorfer, M.M. (2006) Long-term-care placement and survival of persons with Alzheimer’s disease. Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 61, P220- P227. doi:10.1093/geronb/61.4.P220
[19] Haley, W.E., Gitlin, L.N., Wisniewski, S.R., Mahoney, D.F., Coon, D.W., Winter, L., et al. (2004) Well-being, appraisal, and coping in African-American and Caucasian dementia caregivers: Findings from the REACH study. Aging & Mental Health, 8, 316-329. doi:10.1080/13607860410001728998
[20] Kaiser Family Foundation (2005) State Health Facts.
[21] The Robert Wood Johnson Foundation (2005) Changes in Medicaid physician fees, 1998-2003: Implications for physician participation.
[22] Bachrach, D. (2010) Payment reform: Creating a sus- tainable future for Medicaid. Center for Health Care Strategies, Inc., 1-14.
[23] McCarthy, D. (2009) Aiming higher: Results from a state scorecard on health system performance. The Commonwealth Fund.
[24] O’Brien, E. (2005) Long-term care: Understanding Medi- caid’s role for the elderly and disabled. The Kaiser Com- mission on Medicaid and the Uninsured.
[25] Sparer, M., Glied, S. and Vanneman, M. (2005) Medicaid in New Jersey: Options for reform. Hall Institute of Public Policy, New Jersey, 1-12.
[26] Fossett, J.W. and Burke, C.E. (2010) Medicaid policy and long-term care spending. Health Policy Research Center. The Nelson A. Rock-efeller Institute of Government, University at Albany State University of New York.
[27] Cappell, J., Herrmann, N., Cornish, S. and Lanctot, K.L. (2010) The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs, 24, 909-927. doi:10.2165/11539530-000000000-00000
[28] Gilligan, A.M., Malone, D.C., Warholak, T.L. and Armstrong, E.P. (2012) Health disparities in cost of care in patients with Alzheimer’s disease: An analysis across 4 state Medicaid populations. American Journal of Alzheimer’s Disease and Other Dementias, 28, 84-92.
[29] Kruse, R.L., Mehr, D.R., Boles, K.E., Lave, J.R., Binder, E.F., Madsen, R., et al. (2004) Does hospitalization impact survival after lower respiratory infection in nursing home residents? Medical Care, 42, 860-870. doi:10.1097/01.mlr.0000135828.95415.b1
[30] Loeb. M., Carusone, S. C., Goeree, R., Walter, S.D., Brazil, K., Krueger, P., et al. (2006) Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: A randomized controlled trial. Journal of the American Medical Association, 295, 2503-2510. doi:10.1001/jama.295.21.2503
[31] Luchins, D.J. and Hanra-han, P. (1993) What is appropriate health care for end-stage dementia? Journal of the American Geriatrics Society, 41, 25-30.
[32] Morrison, R.S. and Siu, A.L. (2000) Survival in end-stage dementia following acute illness. Journal of the American Medical Association, 284, 47-52. doi:10.1001/jama.284.1.47
[33] Beusterien, K.M., Thomas, S.K., Gause, D., Kimel, M., Arcona, S. and Mirski, D. (2004) Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs, 18, 1143-1148. doi:10.2165/00023210-200418150-00008
[34] Lopez, O.L., Becker, J.T., Wisniewski, S., Saxton, J., Kaufer, D.I. and DeKosky, S.T. (2002) Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 72, 310-314. doi:10.1136/jnnp.72.3.310
[35] Knopman, D., Schneider, L., Davis, K., Talwalker, S., Smith, F., Hoover, T., et al. (1996) Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, tacrine study group. Neurology, 47, 166-177. doi:10.1212/WNL.47.1.166

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.